Nanostructured lipid carriers-based drug delivery for treating various lung diseases: A State‐of‐the‐Art Review
- 1 August 2018
- journal article
- review article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 547 (1-2) , 209-225
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- Inhaled pyrazinamide proliposome for targeting alveolar macrophagesDrug Delivery, 2012
- Levofloxacin-Proliposomes: Opportunities for Use in Lung TuberculosisPharmaceutics, 2012
- Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticlesInternational Journal of Nanomedicine, 2012
- Nanostructured Lipid Carriers (NLC) for Parenteral Delivery of an Anticancer DrugAAPS PharmSciTech, 2011
- Isoniazid Proliposome Powders for Inhalation—Preparation, Characterization and Cell Culture StudiesInternational Journal of Molecular Sciences, 2011
- Acute Lung Injury: Epidemiology, Pathogenesis, and TreatmentJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriersJournal of Controlled Release, 2010
- Acute lung injury and acute respiratory distress syndromeJournal of Emergencies, Trauma, and Shock, 2010
- Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airwayPulmonary Pharmacology & Therapeutics, 2008
- Nanomedicine for respiratory diseasesEuropean Journal of Pharmacology, 2006